Patent · US Active

RSV RNA molecules and compositions for vaccination

US12097253B2 · kind B2 · utility

1Cited by

8References

45Claims

0Family size

Assignee

CureVac SE · DE

Inventors

Johannes LUTZ · Tübingen, DE
Susanne RAUCH · Tübingen, DE
Regina HEIDENREICH · Tübingen, DE
Benjamin PETSCH · Tübingen, DE

Key dates

Filing date	Feb 28, 2024
Grant date	Sep 24, 2024
Priority date	—
Expiry date	Feb 28, 2044

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2760/18534
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention is directed to an artificial nucleic acid, particularly to an artificial RNA suitable for use in treatment and/or prophylaxis of an infection with Respiratory syncytial virus (RSV) or a disorder related to such an infection. The invention further concerns a method of treating or preventing a disorder or a disease, first and second medical uses of the artificial RNA, compositions, and vaccines. Further, the invention is directed to a kit, particularly to a kit of parts, comprising the artificial RNA, compositions and vaccines.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.